# A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

> **NCT05429398** · PHASE1 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 118 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Linperlisib Tablet

## Key facts

- **NCT ID:** NCT05429398
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-05-30
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429398, "A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05429398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*